trending Market Intelligence /marketintelligence/en/news-insights/trending/Y8C2ab4g8M2mvjrDUNooYA2 content esgSubNav
In This List

Summit Therapeutics closes $25M placement of American depositary shares

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Summit Therapeutics closes $25M placement of American depositary shares

Summit Therapeutics PLC completed a private placement of 15,625,000 American depositary shares at $1.60 apiece to raise $25 million.

The ADS in the offering represented 78,125,000 new ordinary shares of Summit Therapeutics.

U.K.-based Summit Therapeutics said the new ordinary shares sold under the placement were listed on the London Stock Exchange's AIM market and started trading Jan. 9.

Summit Therapeutics is a biopharmaceutical company that focuses on the discovery, development and commercialization of novel medicines to treat rare and infectious diseases.